Medtronic Jewels get FDA clearance:
This article was originally published in Clinica
The US FDA has cleared two of Medtronic's Jewel defibrillators for commercial release. Jewel models 7219C and 7202C use Medtronic's active can technology which, in clinical trials of 475 patients significantly lowered average defibrillation thresholds. The single Transvene lead system reduces extraneous electrical noise which could be misinterpreted by the circuitry, says Medtronic. Model 7202C offers cardioversion and defibrillation, while the 7219C also offers anti-tachycardia pacing.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.